A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli

Infection Clinical Trial

Official title:

Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) (A Post-Intervention Surveillance Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00724919
• Other study ID #: 0910X-101440
• Status: Completed
• Phase: N/A
• First received: July 23, 2008
• Last updated: August 7, 2008
• Start date: December 2003
• Est. completion date: April 2004

Study information

• Verified date: August 2008
• Source: Wyeth is now a wholly owned subsidiary of Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Observational

Clinical Trial Summary

To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, post- intervention in the selected medical centres

Description:

This is post-interventional study to follow the acquisition rate of ESBP producing E. coli or K. pneumoniae at the sites involved in a previous interventional study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 256
• Est. completion date: April 2004
• Est. primary completion date: April 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion

1. All patients admitted or transferred to ICU/burn unit.

2. Patients of either sex, 18 years of age or older. Exclusion

Patients were excluded if they had underlying conditions or diseases that were ultimately fatal within 48 hours

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Infection

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Wyeth is now a wholly owned subsidiary of Pfizer

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The acquisition rate of ESBL producing E. coli or K. pneumoniae at the end of surveillance phase		48hours	No
Secondary	The infection rate due to ESBL producing E. coli, or due to K. pneumoniae at the end of surveillance phase		48hours	No